Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Background Recently, therapeutic antibodies against programmed cell death 1 (PD-1) and
its ligand (PD-L1) have exerted potent anticancer effect in a variety of tumors. However …
its ligand (PD-L1) have exerted potent anticancer effect in a variety of tumors. However …
Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung …
S Suzuki, K Haratani, H Hayashi, Y Chiba… - European Journal of …, 2022 - Elsevier
Background Tumour burden (TB) is implicated in resistance to programmed cell death-1/PD-
L1 inhibitor (immune checkpoint inhibitor [ICI]) therapy. However, whether TB contributes to …
L1 inhibitor (immune checkpoint inhibitor [ICI]) therapy. However, whether TB contributes to …
Role of IL-23 signaling in the progression of premalignant oral lesions to cancer
B Caughron, Y Yang, MRI Young - PloS one, 2018 - journals.plos.org
Mice bearing carcinogen-induced premalignant oral lesions were previously shown to have
a pro-inflammatory phenotype, which is replaced with an immune inhibitory phenotype as …
a pro-inflammatory phenotype, which is replaced with an immune inhibitory phenotype as …